Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott cost cutting

This article was originally published in The Gray Sheet

Executive Summary

Plan to streamline global manufacturing operations, reduce overall costs and "improve efficiencies" in Abbott's core diagnostics business over the next four years, approved Aug. 19, will result in annual pre-tax savings of over $150 million when completed, according to the company. However, the actions will cost about $370 million on a pre-tax basis "over the next several years," Abbott says. Of the total, the firm anticipates a $140 million charge this quarter, according to an Aug. 21 filing with the Securities and Exchange Commission

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026502

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel